Case Report
BibTex RIS Cite

Varfarin tedavisinde nadiren gözlenen yan etki: Deri nekrozu

Year 2019, , 190 - 191, 28.06.2019
https://doi.org/10.19161/etd.417314

Abstract

Varfarin yaygın olarak tromboembolik hastalıkların önlenmesinde ve tedavisinde kullanılmaktadır. Bununla birlikte varfarin kullanımının, istenmeyen şekilde, varfarin kaynaklı cilt nekrozunun (WISN) da dahil olduğu aşırı-pıhtılaşma koşullarına neden olduğu bilinmektedir. Bu olgu sunumunda, sol kalp yetmezliği sonucu gelişen femoral ven trombozunun tedavisi sebebiyle hastanede yatan ve WISN gözlenen 70 yaşındaki bir erkek hasta tanımlamaktadır. Hastanın öyküsünde ayrıca kolon adenokarsinomu ve karaciğerde çoklu metastatik odaklar bildirilmiştir.

References

  • Nazarian RM, Van Cott EM, Zembowicz A, Duncan LM. Warfarin-induced skin necrosis. J Am Acad Dermatol 2009;61(2):325-32.
  • Kakagia DD, Papanas N, Karadimas E, Polychronidis A. Warfarin-induced skin necrosis. Ann Dermatol 2014;26(1):96-8.
  • Menon N, Sarode R, Zia A. Rivaroxaban dose adjustment using thrombin generation in severe congenital protein C deficiency and warfarin-induced skin necrosis. Blood Adv 2018;2(2):142-5.
  • Chan YC, Valenti D, Mansfield AO, Stansby G. Warfarin induced skin necrosis. Br J Surg 2000;87(3):266-272.
  • Hasegawa H. Clinical assessment of warfarin therapy in patients with maintenance dialysis-clinical efficacy, risks and development of calciphylaxis. Ann Vasc Dis 2017;10(3):170-7.
  • Hamada T, Miyake T, Otsuka M, Iwatsuki K. Warfarin-induced skin necrosis accompanied by aggravation of vasculitis in a patient with cutaneous arteritis. Int J Dermatol 2017;56(7):779-81.

Skin necrosis: An uncommon side effect of warfarin therapy

Year 2019, , 190 - 191, 28.06.2019
https://doi.org/10.19161/etd.417314

Abstract

Warfarin
is commonly used in the treatment and prevention of thromboembolic events.
However, it is known to undesirably cause hypercoagulable conditions, including
warfarin-induced skin necrosis (WISN). This report describes a 70-year-old man presented with an
extensive WISN while an inpatient for treatment of a
left deep femoral
vein thrombosis. He had a background
of
colon adenocarcinoma and multiple metastatic foci in the liver

References

  • Nazarian RM, Van Cott EM, Zembowicz A, Duncan LM. Warfarin-induced skin necrosis. J Am Acad Dermatol 2009;61(2):325-32.
  • Kakagia DD, Papanas N, Karadimas E, Polychronidis A. Warfarin-induced skin necrosis. Ann Dermatol 2014;26(1):96-8.
  • Menon N, Sarode R, Zia A. Rivaroxaban dose adjustment using thrombin generation in severe congenital protein C deficiency and warfarin-induced skin necrosis. Blood Adv 2018;2(2):142-5.
  • Chan YC, Valenti D, Mansfield AO, Stansby G. Warfarin induced skin necrosis. Br J Surg 2000;87(3):266-272.
  • Hasegawa H. Clinical assessment of warfarin therapy in patients with maintenance dialysis-clinical efficacy, risks and development of calciphylaxis. Ann Vasc Dis 2017;10(3):170-7.
  • Hamada T, Miyake T, Otsuka M, Iwatsuki K. Warfarin-induced skin necrosis accompanied by aggravation of vasculitis in a patient with cutaneous arteritis. Int J Dermatol 2017;56(7):779-81.
There are 6 citations in total.

Details

Primary Language English
Subjects Health Care Administration
Journal Section Case Reports
Authors

Tuba Devrim 0000-0002-5321-2002

Serkan Demirkan 0000-0002-3960-3891

Publication Date June 28, 2019
Submission Date January 31, 2018
Published in Issue Year 2019

Cite

Vancouver Devrim T, Demirkan S. Skin necrosis: An uncommon side effect of warfarin therapy. ETD. 2019;58(2):190-1.

1724617243172472652917240      26515    

 26507    26508 26517265142651826513

2652026519